Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Alemtuzumab as a Glucocorticoid-Sparing Agent for Initial Systemic Treatment of Acute Graft-Versus-Host Disease
NCT00410657Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Jul 2006
- Primary completion
- Nov 2006
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab in graft-versus-host disease (GVHD), sponsored by Fred Hutchinson Cancer Center. Started Jul 2006; status: completed.
02
Drugs
alemtuzumab
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT00410657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00410657.